Bioprotection Systems Corporation, was acquired by NewLink Genetics (NASDAQ: NLNK) and continues to operate as a wholly owned subsidiary of NewLink Genetics. The company is discovering, developing and commercializing novel immunotherapeutic products that improve the strength of the human body to fight cancer. The company is focused on the development of different technologies that could stimulate an antitumor response or address tumor-related immunosuppressionâa combined effort that could provide the greatest chance of treatment success. The firmâs pipeline includes HyperAcute immunotherapies that stimulate the immune system to target and destroy cancer cells, as well as indoleamine 2,3-dioxygenase (IDO) pathway inhibitors that suppress the mechanisms by which tumors evade immune-mediated destruction. The lead HyperAcute immunotherapy product candidate, algenpantucel-L, is being studied in two phase 3 trials in pancreatic cancer. The second HyperAcute immunotherapy candidate, tergenpumatucel-L, is being studied in a phase 2b/3 study in non-small cell lung cancer. Multiple additional HyperAcute immunotherapies are in development for various cancers, including melanoma, prostate cancer, renal cancer, and others. The lead IDO pathway inhibitor, indoximod, is being investigated as part of various combination regimens in metastatic breast cancer, metastatic prostate cancer, and other cance
